All News
Risks associated with mortality in VEXAS
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.
Read ArticleFDA Puts Boxed Warnings on JAK Inhibitors
Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor. These recommendations apply to tofacitinib, baricitinib and upadacitinib.
Read Article
Links:

Links:

Links:

Links:

Links:

Dr. John Cush RheumNow ( View Tweet)

Links:

Download Available! AOSD Disease Patterns Over Time https://t.co/qZBtCQ2QAg https://t.co/fMmN1PAzFG
Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links: